Hamostaseologie 1989; 09(04): 182-189
DOI: 10.1055/s-0038-1655268
Originalarbeiten
Schattauer GmbH

Zur Prophylaxe des Reinfarkts nach Thrombolyse in der Reperfusionsphase sowie nach perkutaner transluminärer koronarer Angioplastie (PTCA) mit Heparin, Azetylsalizylsäure (ASS) oder deren Kombination

R Schmutzler
1   Wuppertal
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
25. Juni 2018 (online)

 

 
  • LITERATUR

  • 1 APSAC-Studiengruppe:. Chamberlain D A, de Bosco D P, Fox K A A, Murray R G. Wirkung von intravenösem APSAC auf die Letalität nach akutem Myokardinfarkt: Vorläufiger Bericht über eine plazebokontrollierte klinische Prüfung. Lancet (deutsche Ausgabe) 1988; 02: 425-30.
  • 2 Barthels M, Möller W, Gulba D C, Bohn U, Oesterreich C h, Poliwoda H. Elevated levels of thrombin-antithrombin complex in plasma in vitro and in vivo after addition of pro-urokinase-urokinase. Blut 1989; 58: 116 (Abstr 92).
  • 3 Bieler L. How might thrombolytic therapy actually be encouraging platelet aggregation and reocclusion?. Cardio. 1988 November: 93-94.
  • 4 Bleyl H, Pelzer H, Heimburger N. Immunoradiometric assay for measuring the thrombin-antithrombin complex. Haemostasis 1985; 15: 79.
  • 5 Breddin H K. Persönliche Mitteilung. 1989
  • 6 DeCaterina R, Giannessi D, Bernini W, Grazzetti P, Michelassi C, L’Abbate A, Donato L, Patrignani P, Filabozzi P, Patrano C. Seletive inhibition of thromboxanrelated platelet function by low-dose aspirin in patients after myocardial infarction. Am J Cardiol 1985; 55: 589.
  • 7 Chesebro J H, Fuster V. Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thrombo-embolism. Circulation 1986; 74 (Suppl 3): 1-10.
  • 8 Collen D. Synergism of thrombolytic agents: investigational procedures and clinical potential. Circulation 1988; 77: 731-35.
  • 9 Davies M J, Thomas A C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
  • 10 Eisenberg P R, Sherman L A, Jaffe A S. Paradoxic elevation of fibrinopeptide A after Streptokinase: evidence for continued thrombosis despite intense fibrinolysis. JACC 1987; 10: 527-29.
  • 11 Erbel R, Pop T v, Olshausen K E, Meinertz T, Henkel B, Schreiner B, Henrichs K J, Rupprecht H J, Zahn R, Steuernagel C, Beck F, Meyer J. Thrombolytische Therapie und Ballondilatation. Dtsch med Wschr 1986; 111: 523-29.
  • 12 Essen v R, Uebis R, Schmidt W, Dörri R, Merx W, Meyer J, Effert S, Schweizer R, Erbel R, Bardos P, Minale C, Messmer B J. Intrakoronare Streptokinase beim akuten Herzinfarkt. Dtsch med Wschr 1985; 110: 570-75.
  • 13 Europäische rt-PA-Studiengruppe:. Simoons M L, Arnold A E R, Betrin A, DeBono D P, Col J, Dougherty F C v, Essen R, Lambertz H, Lubsen J, Meier B, Michel P L, Raynaud P, Rutsch W, Sanz G A, Schmidt W, Serruys P W, Thery C, Uebis R, Vahanian A, Van de Werf F, Willems G M, Wood D, Verstraete M. Thrombolyse mit Gewebe-Plasminogen-Aktivator beim akuten Myokardinfarkt: Kein zusätzlicher Nutzen durch sofortige perkutane Koronarangioplastie. Lancet (deutsche Ausgabe) 1988; 02: 238-44.
  • 14 Falk E. Plaque rupture with severe preexisting stenosis precepitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlussive thrombi. Br Heart J 1983; 50: 127-34.
  • 15 Fitzgerald D J. Platelet-dependent reocclusion following coronary thrombolysis with tissue plasminogen activator. Clin Res 1987; 35: 278 A.
  • 16 Fitzgerald D J, Catella F, Roy L, Fitzgerald G A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-50.
  • 17 Francis C W, Markham R E, Barlow G H, Florack T M, Dobrzynski D M, Marder V J. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-30.
  • 18 Fuster V, Steele P M, Chesebro J H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. JACC 1985; 05: 175B-84B.
  • 19 Fuster V, Stein B, Badimon L, Chesebro J H. Antithrombolytic therapy after myocardial reperfusion in acute myocardial infarction. JACC 1988; 12: 78A-84A.
  • 20 Fuster V, Badimon L, Cohen M, Ambrose J A, Badimon J J, Chesebro J H. Insights into the pathogenesis of acute ischemic syndromes. Circulation 1988; 77: 1213-20.
  • 21 Fuster V, Cohen M, Chesebro J H. Usefulness of aspirin for coronary artery disease. Am J Cardiol 1988; 61: 637-40.
  • 22 Gabliani G, Deligonul U, Kern M J, Vandormael M. Acute coronary occlusion occuring after successful percutaneous transluminal coronary angioplasty: temporal relationship to discontinuation of anticoagulation. Am Heart J 1988; 116: 696-700.
  • 23 Gash A K, Spann J F, Sherry S. Factors influencing reocclusion after coronary thrombolysis for acute myocardial infarction. Am J Cardiol 1986; 57: 175-77.
  • 24 Gold H K, Leinbach R C, Palacios J F, Yasuda T, Block P C, Buckley M J, Atkins C W, Dagett W M, Austen W G. Coronary reocclusion after selective administration of SK. Circulation 1983; 68: 150-54.
  • 25 Gold M, Cowley J, Palacios I F, Vetrovec G W, Atkins C W, Block P C, Leinbach R C. Combined intracoronary streptokinase infusion and coronary angioplasty during acute myocardial infarction. Am J Cardiol 1984; 53: 122.
  • 26 Gold H K. et al. Rapid and sustained coronary artery recanalisation with combined bolus injection of recombinant tissuetype plasminogen activator and monoclonal antiplatelet GP Ilb-IIIa antibody in a canine preparation. Circulation 1988; 77: 670-77.
  • 27 Golino P. et al.: Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678-84.
  • 28 Gulba D C, Barthels M, Reil G-H, Lichtlen P R. Thrombin/antithrombin-III complex level as early predictor of reocclusion after succesful thrombolysis. Lancet 1988; July 09: 97-8.
  • 29 Gulba D C, Reil G-H, Barthels M, Möller W, Jost S, Amende I, Lichtlen P R. Thrombolysis for acute thrombolytic reocclusion during percutaneous transluminal coronary angioplasty. Blut 1989; 58: 107 (Abstr 53).
  • 30 Hackett D, Davies G, Chierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilatator therapy. N Engl J Med 1987; 317: 1055-59.
  • 31 Harrison D G, Ferguson D S W, Collins S T M, Skorton D J, Ericksen E E, Kioschos J M, Marcus M L, White C W C. Rethrombosis after reperfusion streptokinase: importance of geometry of residual lesions. Circulation 1984; 69: 991-99.
  • 32 Heinrich D, Bandemer G, Hellwig A, Kempf K P, Firnkranz E, Bleyl H, Ditter H, Müller-Berghaus G. Zur Frage der adjuvanten Therapie mit Heparin und Azetylsalizylsäure bei hochdosierter Kurzzeit-Streptokinaselyse von Patienten mit akutem Myokardinfarkt. In: Thrombolytische Therapie des akuten Myokardinfarktes. Köstering H, Kreuzer H, Neuhaus K L. (Hrsg). Stuttgart - New York: Schattauer; 1986: 123-32.
  • 33 Kyrie P A, Eichler H G, Jager U, Lechner K. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation 1987; 75: 1025-29.
  • 34 Loscalzo J, Vaughan D E. Tissue plasminogen activator promotes platelet disaggregation in plasma. J Clin Invest 1987; 79: 1749.
  • 35 Marder V J, Sherry S. Thrombolytic therapy: current status (first part). N Engl J Med 1988; 318: 1512-20.
  • 36 Meyer J. Prevention of reocclusion after PTC A and coronary bypass surgery. Thromb Res 1988; Suppl IX: 31-2.
  • 37 Neuhaus K L, Tebbe U, Gottwik M, Weber M A J, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser K D, Huhmann W, Hoepp H W, Alber G, Sheikhzadeh A, Schneider B. Intravenöse Infusion von recombinant tissue plasminogen activator (rt-PA) und Urokinase beim akuten Myokardinfarkt: Zwischenergebnisse der G. A. U. S.-Studie (German Activator Urokinase Study). Klin Wochenschr. 1988. (Suppl XII): 102-8.
  • 38 Ohlstein E H, Shebuski R J. Tissue-type plasminogen activator (t-PA) increases plasma thromboxane levels which is associated with platelet hyperaggregation. Circulation 1987; 76 (Suppl IV): 100 (Abstr).
  • 39 Owen J, Friedman K D, Grossmann B A, Wilkins C, Berke A J, Powers E R. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616-20.
  • 40 Özbek C, Schwerdt H v, Blohn G, Köhler M, Doenecke P. Systemische Ultrakurzlyse des akuten Myokardinfarkts. II. Klinische Ergebnisse. Herz/Kreislauf 1986; 03: 120-23.
  • 41 Ring M E, Butman S M, Bruck D C, Feinberg W M, Corrigan J J. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator. Thromb Haemost 1988; 60: 428-33.
  • 42 Schaer D H, Leibhoff R H, Katz R J. Recurrent early ischemic events after thrombolysis for acute myocardial infarction. Am J Cardiol 1987; 59: 788-92.
  • 43 Schwarz F, König B, Tillmanns H. Thrombolyse bei akutem Herzinfarkt. Verbesserte Langzeitprognose nach Ballondilatation. Dtsch med Wschr 1987; 112: 331-34.
  • 44 Schwerdt H, Özbek C, Hellstern P, Wenzel E, Doenecke P. Systemische Ultrakurzlyse des akuten Myokardinfarktes. I. Gerinnungsphysiologische Ergebnisse. Herz/ Kreislauf 1986; 03: 115-9.
  • 45 Shebuski R J, Ohlstein E H. Attenuation of platelet responsiveness to prostacyclin (PGI2) after tissue-type plasminogen activator (t-PA). Ciruculation. 1987 76. IV-338 (Abstr).
  • 46 TAMI (Thrombolysis and Angioplasty in Myocardial Infarction Trials):. Topol E J, Califf R M, George B S, Kereiakes D J, Lee K L. Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. JACC 1988; 12: 24A-31A.
  • 47 bTIMI-II (Thrombolysis in Myocardial Infarction):. Mueller H S, Rao A K, Forman S A. and the TIMI Investigators: Comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogenactivator. JACC 1987; 10: 479-90.
  • 48 Timmis G C, Mammen E F, Ramos R G. Hemorrhage vs rethrombosis after thrombolysis for acute myocardial infarction. Arch Intern Med 1986; 146: 667-72.
  • 49 Uebis R, Dörr K, Reynen K, Effert S K. Reokklusion nach erfolgreicher thrombolytischer Therapie beim akuten Myokardinfarkt. Klin Wochenschr 1988; 66 (Suppl XII): 115-18.
  • 50 Vaughan D E, Kirshenbaum J M, Loscalzo J. Streptokinase-induced, antibody-mediated platelet aggregation a potential cause of clot propagation in vivo. JACC 1988; 11: 1343-48.
  • 51 Van de Werf F. Coronary thrombolysis and reocclusion: where do we stand?. Thromb Res 1988; (Suppl IX): 27-9.
  • 52 Williams D O, Borer J, Braunwald E. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338-46.